An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine.
Mammary cancer is among the most prevalent canine tumors and frequently resulting in death due to metastatic disease that is highly homologous to human breast cancer. Most canine tumors fail to raise effective immune reactions yet, some spontaneous remissions do occur. Hybrid canine dendritic cell-tumor cell fusion vaccines were designed to enhance antigen presentation and tumor immune recognition. Peripheral blood-derived autologous dendritic cell enriched populations were isolated from dogs based on CD11c(+) expression and fused with canine mammary tumor (CMT) cells for vaccination of laboratory Beagles. These hybrid cells were injected into popliteal lymph nodes of normal dogs, guided by ultrasound, and included CpG-oligonucleotide adjuvants. Three rounds of vaccination were delivered. Significant IgG responses were observed in all vaccinated dogs compared to vehicle-injected controls. Canine IgG antibodies recognized shared CMT antigens as was demonstrated by IgG-recognition of three unrelated/independently derived CMT cell lines, and recognition of freshly isolated, unrelated, primary biopsy-derived CMT cells. A bias toward an IgG2 isotype response was observed after two vaccinations in most dogs. Neither significant cytotoxic T cell responses were detected, nor adverse or side-effects due to vaccination or due to the induced immune responses noted. These data provide proof-of-principle for this cancer vaccine strategy and demonstrate the presence of shared CMT antigens that promote immune recognition of mammary cancer.
Department of Pathobiology, Auburn University, Auburn, AL 36849-5519, USA. birdric@vetmed.auburn.edu
R Curtis
RC
Bird
Patricia
P
Deinnocentes
Allison E
AE
Church Bird
Frederik W
FW
van Ginkel
Joni
J
Lindquist
Bruce F
BF
Smith
D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines; D002459:Cell Fusion / Q000379:methods; D045744:Cell Line, Tumor; D002469:Cell Separation; D002678:Chimera / Q000276:immunology / Q000378:metabolism*; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D004285:Dogs; D005260:Female; D005434:Flow Cytometry; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000097:blood; D008213:Lymphocyte Activation; D015674:Mammary Neoplasms, Animal / Q000097:blood / Q000276:immunology* / Q000473:pathology / Q000628:therapy*
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D007074:Immunoglobulin G